{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:18:09Z","timestamp":1788013089714,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hebei Provincial Medical Science Research Project Plan","award":["20250369"],"award-info":[{"award-number":["20250369"]}]},{"name":"Hebei Provincial Medical Science Research Project Plan","award":["20250369"],"award-info":[{"award-number":["20250369"]}]},{"name":"Hebei Provincial Medical Science Research Project Plan","award":["20250369"],"award-info":[{"award-number":["20250369"]}]},{"name":"Hebei Provincial Medical Science Research Project Plan","award":["20250369"],"award-info":[{"award-number":["20250369"]}]},{"name":"Hebei Provincial Medical Science Research Project Plan","award":["20250369"],"award-info":[{"award-number":["20250369"]}]},{"name":"Hebei Provincial Medical Science Research Project Plan","award":["20250369"],"award-info":[{"award-number":["20250369"]}]},{"name":"Hebei Provincial Medical Science Research Project Plan","award":["20250369"],"award-info":[{"award-number":["20250369"]}]},{"name":"Hebei Provincial Healthcare Security Research Project","award":["JYB240310"],"award-info":[{"award-number":["JYB240310"]}]},{"name":"Hebei Provincial Healthcare Security Research Project","award":["JYB240310"],"award-info":[{"award-number":["JYB240310"]}]},{"name":"Hebei Provincial Healthcare Security Research Project","award":["JYB240310"],"award-info":[{"award-number":["JYB240310"]}]},{"name":"Hebei Provincial Healthcare Security Research Project","award":["JYB240310"],"award-info":[{"award-number":["JYB240310"]}]},{"name":"Hebei Provincial Healthcare Security Research Project","award":["JYB240310"],"award-info":[{"award-number":["JYB240310"]}]},{"name":"Hebei Provincial Healthcare Security Research Project","award":["JYB240310"],"award-info":[{"award-number":["JYB240310"]}]},{"name":"Hebei Provincial Healthcare Security Research Project","award":["JYB240310"],"award-info":[{"award-number":["JYB240310"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s43441-026-00979-z","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:07:26Z","timestamp":1779973646000},"page":"1440-1452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacoeconomic Evaluation of Netupitant Palonosetron for Chemotherapy-Induced Nausea and Vomiting: Evidence from Economic Analyses"],"prefix":"10.1007","volume":"60","author":[{"given":"Meiyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"6","key":"979_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260\u20137.","journal-title":"Ann Oncol"},{"key":"979_CR2","doi-asserted-by":"crossref","unstructured":"Lorusso D et al. Patients\u2019 perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey. Eur J Cancer Care (Engl), 2017. 26(2).","DOI":"10.1111\/ecc.12618"},{"key":"979_CR3","first-page":"100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021;26:100278.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"979_CR4","first-page":"e1127","volume":"1","author":"M Aapro","year":"2018","unstructured":"Aapro M, et al. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken). 2018;1(4):e1127.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"4","key":"979_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/MCG.0000000000001485","volume":"55","author":"M Heckroth","year":"2021","unstructured":"Heckroth M, et al. Nausea and vomiting in 2021: a comprehensive update. J Clin Gastroenterol. 2021;55(4):279\u201399.","journal-title":"J Clin Gastroenterol"},{"issue":"39","key":"979_CR6","first-page":"3080","volume":"102","author":"CSoC Oncology","year":"2022","unstructured":"Oncology CSoC. Chinese society of cancer supportive care. Chinese expert consensus on the prevention and treatment of nausea and vomiting associated with antineoplastic drugs (2022 edition). Natl Med J China. 2022;102(39):3080\u201394.","journal-title":"Natl Med J China"},{"key":"979_CR7","unstructured":"NCCN. National comprehensive cancer network. clinical practice guidelines in oncology: antiemesis. v. 1.2022; 2022."},{"issue":"3","key":"979_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","volume":"73","author":"RM Navari","year":"2013","unstructured":"Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73(3):249\u201362.","journal-title":"Drugs"},{"issue":"8","key":"979_CR9","first-page":"750","volume":"26","author":"Y Yunpeng","year":"2021","unstructured":"Yunpeng Y. Netupitant and palonosetron hydrochloride capsules, a new fixed-dose combination drug for the prevention of chemotherapy-induced nausea and vomiting. Chin Clin Oncol. 2021;26(8):750\u20135.","journal-title":"Chin Clin Oncol"},{"issue":"24","key":"979_CR10","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397.","journal-title":"J Clin Oncol"},{"key":"979_CR11","doi-asserted-by":"crossref","unstructured":"Roila F et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol, 2016. 27(suppl 5):119\u2013133.","DOI":"10.1093\/annonc\/mdw270"},{"issue":"12","key":"979_CR12","first-page":"1325","volume":"38","author":"Zhang","year":"2018","unstructured":"Zhang, Bin. L.I.X.-l., Adherence to clinical guidelines for prophylaxis of chemotherapy induced nausea and vomiting. Chin J Hosp Pharm. 2018;38(12):1325\u20139.","journal-title":"Chin J Hosp Pharm"},{"issue":"2","key":"979_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang L, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452\u20138.","journal-title":"Ann Oncol"},{"issue":"14","key":"979_CR14","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1002\/cam4.3123","volume":"9","author":"J Chang","year":"2020","unstructured":"Chang J, et al. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Cancer Med. 2020;9(14):5134\u201342.","journal-title":"Cancer Med"},{"key":"979_CR15","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.hpopen.2021.100063","volume":"3","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Health Policy Open. 2022;3:100063.","journal-title":"Health Policy Open"},{"key":"979_CR16","doi-asserted-by":"crossref","unstructured":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 Explanation and elaboration: a report of the ISPOR CHEERS Ii good practices task force. Value Health, 2022. 25(6):1060.","DOI":"10.1016\/j.jval.2022.03.002"},{"issue":"11","key":"979_CR17","first-page":"1368","volume":"33","author":"Q Ran","year":"2022","unstructured":"Ran Q, et al. A systematic review of the cost-effectiveness of therapeutic drugs for anaplastic lymphoma kinase-positive non-small cell lung cance. China Pharm. 2022;33(11):1368\u201373.","journal-title":"China Pharm"},{"issue":"17","key":"979_CR18","first-page":"2257","volume":"39","author":"D Liangliang","year":"2022","unstructured":"Liangliang D, Kun L, Xiuhua W. Cost-utility analysis of drugs for prevention and treatment of chemotherapy-induced nausea and vomiting. Chin J Mod Appl Pharm. 2022;39(17):2257\u201361.","journal-title":"Chin J Mod Appl Pharm"},{"issue":"7","key":"979_CR19","first-page":"11","volume":"18","author":"C Li-Li","year":"2023","unstructured":"Li-Li C, et al. Cost-effectiveness of netupitant-palonosetron capsule in the treatment of chemotherapy-induced nausea and vomiting. Chin J Pharmacoeconomics. 2023;18(7):11\u20136.","journal-title":"Chin J Pharmacoeconomics"},{"issue":"8","key":"979_CR20","first-page":"956","volume":"44","author":"Z Yu","year":"2024","unstructured":"Yu Z, et al. Pharmacoeconomic evaluation of netupitant\/palonosetron for preventing carboplatin-induced nausea and vomiting under diagnosis-related groups payment system. Chin J Hosp Pharm. 2024;44(8):956\u201360.","journal-title":"[Chin J Hosp Pharm"},{"issue":"2","key":"979_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00520-019-04824-y","volume":"28","author":"M Botteman","year":"2020","unstructured":"Botteman M, et al. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR\u2009+\u2009GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer. 2020;28(2):857\u201366.","journal-title":"Support Care Cancer"},{"key":"979_CR22","doi-asserted-by":"publisher","first-page":"212298","DOI":"10.7573\/dic.212298","volume":"6","author":"H Cawston","year":"2017","unstructured":"Cawston H, et al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017;6:212298.","journal-title":"Drugs Context"},{"issue":"11","key":"979_CR23","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.1007\/s00520-022-07339-1","volume":"30","author":"J Nilsson","year":"2022","unstructured":"Nilsson J, et al. Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Support Care Cancer. 2022;30(11):9307\u201315.","journal-title":"Support Care Cancer"},{"issue":"7","key":"979_CR24","doi-asserted-by":"publisher","first-page":"e015645","DOI":"10.1136\/bmjopen-2016-015645","volume":"7","author":"U Restelli","year":"2017","unstructured":"Restelli U, et al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open. 2017;7(7):e015645.","journal-title":"BMJ Open"},{"issue":"5","key":"979_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/14737167.2019.1650644","volume":"19","author":"J Giuliani","year":"2019","unstructured":"Giuliani J, Bonetti A. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment. Expert Rev PharmacoEcon Outcomes Res. 2019;19(5):505\u20138.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"1","key":"979_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/fon-2022-0972","volume":"19","author":"WW Nelson","year":"2023","unstructured":"Nelson WW, et al. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy. Future Oncol. 2023;19(1):29\u201336.","journal-title":"Future Oncol"},{"issue":"8","key":"979_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00520-007-0349-1","volume":"16","author":"L Annemans","year":"2008","unstructured":"Annemans L, et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer. 2008;16(8):905\u201315.","journal-title":"Support Care Cancer"},{"issue":"2","key":"979_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejca.2006.09.019","volume":"43","author":"F Lordick","year":"2007","unstructured":"Lordick F, et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer. 2007;43(2):299\u2013307.","journal-title":"Eur J Cancer"},{"issue":"4","key":"979_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00002820-199708000-00005","volume":"20","author":"S B\u00f6rjeson","year":"1997","unstructured":"B\u00f6rjeson S, et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs. 1997;20(4):260\u20136.","journal-title":"Cancer Nurs"},{"issue":"6","key":"979_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/BF01880641","volume":"4","author":"SM Grunberg","year":"1996","unstructured":"Grunberg SM, et al. Impact of nausea\/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer. 1996;4(6):435\u20139.","journal-title":"Support Care Cancer"},{"issue":"7","key":"979_CR31","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340\u20136.","journal-title":"Ann Oncol"},{"issue":"7","key":"979_CR32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328\u201333.","journal-title":"Ann Oncol"},{"issue":"9","key":"979_CR33","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/cncr.23364","volume":"112","author":"JD Herrington","year":"2008","unstructured":"Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112(9):2080\u20137.","journal-title":"Cancer"},{"key":"979_CR34","unstructured":"Yaozhi D. 2021 [2021-11-2]."},{"issue":"3","key":"979_CR35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","volume":"27","author":"S Chanthawong","year":"2019","unstructured":"Chanthawong S, et al. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer. 2019;27(3):1109\u201319.","journal-title":"Support Care Cancer"},{"issue":"1","key":"979_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1006\/gyno.2002.6807","volume":"87","author":"CC Sun","year":"2002","unstructured":"Sun CC, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87(1):118\u201328.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"979_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17(6):1000\u20136.","journal-title":"Ann Oncol"},{"key":"979_CR38","unstructured":"Q1 CMS Payment Lions and 2018 CMS Medicare Fee Schedule (2018) retrieved from CMS, centers for medicare & medicaid services. 2018; Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/"},{"key":"979_CR39","unstructured":"PBMI drug benefit report (2015). 2018; Available from: https:\/\/www.pbmi.com\/ItemDetail?iProductCode=2014-2015_BDRCategory=BDRWebsiteKey=0a635f1b-bb59-4687-8a69-2a4c2892992b"},{"issue":"1","key":"979_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","volume":"19","author":"TA Burke","year":"2011","unstructured":"Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131\u201340.","journal-title":"Support Care Cancer"},{"key":"979_CR41","unstructured":"Benson AB et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2024;22(2d)."},{"issue":"31","key":"979_CR42","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189\u201398.","journal-title":"J Clin Oncol"},{"key":"979_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S44539","volume":"5","author":"S Humphreys","year":"2013","unstructured":"Humphreys S, Pellissier J, Jones A. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res. 2013;5:215\u201324.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"979_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1758834016654902","volume":"8","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman O. Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. Ther Adv Med Oncol. 2016;8(5):396\u2013406.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"979_CR45","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdh110","volume":"15","author":"A Ihbe-Heffinger","year":"2004","unstructured":"Ihbe-Heffinger A, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15(3):526\u201336.","journal-title":"Ann Oncol"},{"issue":"7","key":"979_CR46","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25(7):1333\u20139.","journal-title":"Ann Oncol"},{"key":"979_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40780-018-0128-9","volume":"4","author":"H Shimizu","year":"2018","unstructured":"Shimizu H, et al. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). J Pharm Health Care Sci. 2018;4:31.","journal-title":"J Pharm Health Care Sci"},{"issue":"3","key":"979_CR48","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cncr.22823","volume":"110","author":"YC Tina Shih","year":"2007","unstructured":"Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678\u201385.","journal-title":"Cancer"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00979-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00979-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00979-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:47:09Z","timestamp":1788011229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00979-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00979-z","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}